HUP0400579A2 - Tetralonszármazékok mint tumorellenes gyógyászati hatóanyagok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Tetralonszármazékok mint tumorellenes gyógyászati hatóanyagok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0400579A2
HUP0400579A2 HU0400579A HUP0400579A HUP0400579A2 HU P0400579 A2 HUP0400579 A2 HU P0400579A2 HU 0400579 A HU0400579 A HU 0400579A HU P0400579 A HUP0400579 A HU P0400579A HU P0400579 A2 HUP0400579 A2 HU P0400579A2
Authority
HU
Hungary
Prior art keywords
group
4alkyl
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0400579A
Other languages
English (en)
Inventor
Guy Georges
Adelbert Grossmann
Tim Sattelkau
Wolfgang Schaefer
Ulrich Tibes
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of HUP0400579A2 publication Critical patent/HUP0400579A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány (I) általános képletű vegyületekre, ezek előállítására ésaz e vegyületeket tartalmazó, HDAC inhibítor aktivitással rendelkezőgyógyászati készítményekre vonatkozik. A képletben Rl jelentésehidrogénatom, 1-4 szénatomos alkilcsoport, karboxilcsoport vagy 1-4szénatomos alkoxi-karbonil-csoport; R2, R3, R4 és R5 jelentéseegymástól függetlenül hidrogénatom, halogénatom, 1-4 szénatomosalkil-, trifluor-metil-, hidroxi-, 1-4 szénatomos alkoxi-, ariloxi-,aralkoxi-, nitro-, amino-, 1-4 szénatomos alkil-amino-, di-(1-4szénatomos alkil)-amino-, piperidino-, morfolino-, pirrolidino-, 1-4szénatomos alkanoil-amino-, aril- vagy heteroaril-csoport; vagy R2 ésR3 együtt, vagy R3 és R4 együtt, vagy R4 és R5 együtt 1-3 szénatomosalkiléndioxi-csoportot képez; vagy R2 és R3 együtt, vagy R3 és R4együtt, vagy R4 és R5 együtt 3-5 szénatomos alkilénláncot képez; Yjelentése -CH2-CH2-; X jelentése 4-10 szénatomos, telített vagytelítetlen, utóbbi esetben egy vagy két kettőskötést vagy egy vagy kéthármaskötést vagy egy kettőskötést és egy hármaskötést tartalmazó,egyenes- vagy elágazóláncú vagy 3-7 szénatomos cikloalkilcsoporttalmegszakított alkiléncsoport. Ó
HU0400579A 2000-12-07 2001-12-06 Tetralonszármazékok mint tumorellenes gyógyászati hatóanyagok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények HUP0400579A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126820 2000-12-07
PCT/EP2001/014311 WO2002046144A1 (en) 2000-12-07 2001-12-06 Tetralone derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
HUP0400579A2 true HUP0400579A2 (hu) 2004-06-28

Family

ID=8170594

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400579A HUP0400579A2 (hu) 2000-12-07 2001-12-06 Tetralonszármazékok mint tumorellenes gyógyászati hatóanyagok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Country Status (26)

Country Link
US (1) US6531472B2 (hu)
EP (1) EP1349830A1 (hu)
JP (1) JP4091431B2 (hu)
KR (1) KR20030077551A (hu)
CN (1) CN100340545C (hu)
AR (1) AR035659A1 (hu)
AU (2) AU1607402A (hu)
BG (1) BG107889A (hu)
BR (1) BR0115988A (hu)
CA (1) CA2430355A1 (hu)
CZ (1) CZ20031833A3 (hu)
EC (1) ECSP034642A (hu)
HK (1) HK1060875A1 (hu)
HR (1) HRP20030451A2 (hu)
HU (1) HUP0400579A2 (hu)
IL (1) IL156133A0 (hu)
MA (1) MA26972A1 (hu)
MX (1) MXPA03004947A (hu)
NO (1) NO20032531D0 (hu)
NZ (1) NZ526051A (hu)
PL (1) PL365324A1 (hu)
RU (1) RU2288220C2 (hu)
SK (1) SK8512003A3 (hu)
WO (1) WO2002046144A1 (hu)
YU (1) YU45803A (hu)
ZA (1) ZA200304262B (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP2269609A3 (en) * 2001-10-16 2012-07-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases and cancer of the brain with SAHA
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
EP2266552A3 (en) 2002-03-04 2011-03-02 Merck HDAC Research, LLC Methods of inducing terminal differentiation
WO2003083067A2 (en) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
EP1492596A1 (en) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004050885A2 (en) * 2002-12-05 2004-06-17 Imperial College Innovations Limited Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
EP1608628A2 (en) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
DK1663194T3 (da) 2003-08-26 2010-07-19 Merck Hdac Res Llc Anvendelse af SAHA til behandling af mesotheliom
EP1667680A4 (en) 2003-08-29 2008-10-08 Aton Pharma Inc COMBINED METHODS OF TREATING CANCER
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050288215A1 (en) * 2004-04-05 2005-12-29 Mckinsey Timothy A Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
WO2005099747A1 (en) * 2004-04-14 2005-10-27 Medical Research Council Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6
KR100632800B1 (ko) 2004-10-21 2006-10-16 한국화학연구원 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
JP2009501236A (ja) * 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2007025177A2 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2012801A4 (en) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP3470536A1 (en) 2013-10-01 2019-04-17 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
AU2014337102B2 (en) * 2013-10-18 2019-02-28 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
US20220153687A1 (en) * 2019-03-29 2022-05-19 Taiwanj Pharmaceuticals Co., Ltd. Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448730A (en) * 1981-03-24 1984-05-15 Riet Bartholomeus Van T Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5637946A (en) * 1993-10-28 1997-06-10 Lockheed Corporation Thermally energized electrical power source
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds

Also Published As

Publication number Publication date
CA2430355A1 (en) 2002-06-13
NO20032531L (no) 2003-06-04
PL365324A1 (en) 2004-12-27
JP4091431B2 (ja) 2008-05-28
AU2002216074B2 (en) 2006-01-05
SK8512003A3 (en) 2004-04-06
IL156133A0 (en) 2003-12-23
YU45803A (sh) 2006-05-25
ECSP034642A (es) 2003-07-25
AU1607402A (en) 2002-06-18
CZ20031833A3 (cs) 2004-02-18
ZA200304262B (en) 2004-08-30
NO20032531D0 (no) 2003-06-04
AU2002216074C1 (en) 2006-12-07
KR20030077551A (ko) 2003-10-01
JP2004515488A (ja) 2004-05-27
BR0115988A (pt) 2004-01-13
MXPA03004947A (es) 2003-09-10
EP1349830A1 (en) 2003-10-08
HRP20030451A2 (en) 2005-04-30
BG107889A (bg) 2004-06-30
CN1478072A (zh) 2004-02-25
WO2002046144A1 (en) 2002-06-13
MA26972A1 (fr) 2004-12-20
CN100340545C (zh) 2007-10-03
AR035659A1 (es) 2004-06-23
US6531472B2 (en) 2003-03-11
RU2288220C2 (ru) 2006-11-27
US20020065282A1 (en) 2002-05-30
NZ526051A (en) 2004-12-24
HK1060875A1 (en) 2004-08-27

Similar Documents

Publication Publication Date Title
HUP0400579A2 (hu) Tetralonszármazékok mint tumorellenes gyógyászati hatóanyagok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0400233A2 (hu) 1-típusú plazminogén aktivátor inhibitor (PAI-1) gátló szubsztituált naftil-indolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0103460A2 (hu) Vírusellenes hatású indolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
HUP0302435A2 (hu) 11-Béta-hidroxiszteroid dehidrogenáz 1 típusú enzimet gátló anyagok és ezeket tartalmazó gyógyszerkészítmények
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
HUP0302980A2 (hu) Lipofil és ionizálható molekularészeket tartalmazó protein junkinázgátló hatású szulfonamid-származékok és ezeket tartalmazó gyógyszerkészítmények
TR199800720T2 (xx) Farnesil transferaz inhibe eden 2-kinolon t�revleri.
MY127718A (en) Dolastatin 10 derivatives.
DE60112609D1 (en) Pyrazolopyridine
CA2305313A1 (en) Acylsulfamoylbenzamides, crop protection compositions comprising them, and processes for their preparation
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0400704A2 (hu) Heterociklusos éterrel szubsztituált imidazokinolinok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ES2140961T3 (es) Nuevos derivados de 19-nor-pregneno.
ATE300541T1 (de) Pyrazolopyridinderivate
HUP0203052A2 (hu) Biciklikus imidazo-3-il-amin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO954072D0 (no) Vannopplöselige camptotecinderivater, fremgangsmåte for deres fremstilling og deres anvendelse som antitumormidler
GEP20022824B (en) Antipicornaviral Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treatment
NO20020282L (no) Nytt difenyl-piperidinderivat
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
MXPA02012569A (es) Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas.
ATE253359T1 (de) Antithrombotische mittel
DE60318874D1 (en) Pyrazolderivate
EA200100059A2 (ru) Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
ATE274515T1 (de) Pyrazolopyridinderivate

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees